Sponsored Content by EvotecReviewed by Emily MageeJul 23 2026
Biomarkers are transforming how diseases are understood, diagnosed, and treated across the evolving drug development landscape
Image Credit: Shutterstock.com/TanyaJoy
Biomarkers act as a scientific bridge between molecular insights and clinical application, from supporting early target validation to guiding clinical trial design and supporting regulatory decisions.
Their role in precision medicine is particularly central, supporting tailored therapeutic approaches based on an individual patient’s or subgroup’s biological profile.
This eBook from Evotec explores the key roles of biomarkers across the drug discovery and development continuum.
Biomarkers are defined and their main types classified, including diagnostic, prognostic, safety, and patient-stratification biomarkers; target engagement and pharmacodynamic biomarkers; and surrogate endpoints. These biomarker types can inform both preclinical research and clinical development.
The eBook also examines the role of biomarkers in advancing precision medicine, including their capacity to improve treatment efficacy, reduce the risk of adverse effects, and help reduce clinical trial attrition.
Practical considerations and regulatory challenges in implementing biomarkers are also highlighted. These elements impact both clinical outcomes and commercial success, from assay validation and reproducibility to data interpretation and regulatory acceptance.
The eBook also explores emerging trends in biomarker discovery, including high-sensitivity detection, multi-omics integration, and artificial intelligence. These innovations offer new ways to improve patient stratification and better understand disease mechanisms.
Finally, a look at real-world applications features case studies and expert insights, demonstrating how biomarker-driven strategies can inform decision-making and accelerate clinical development.
Overall, this eBook offers a forward-thinking, practical overview of how biomarkers can improve patient outcomes and support advances across drug discovery and development.
Acknowledgments
Produced from materials originally authored by Evotec.
About Evotec
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure – faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling.
With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility.
Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology.
Evotec’s global team of more than 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us LinkedIn and X/Twitter @Evotec.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.